Holliday Emma B, Yang George, Jagsi Reshma, Hoffman Karen E, Bennett Katherine Egan, Grace Calley, Zietman Anthony L
Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
The University of South Florida Morsani College of Medicine, Tampa, Florida.
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):3-10. doi: 10.1016/j.ijrobp.2014.10.003.
To evaluate characteristics associated with higher rates of acceptance for original manuscripts submitted for publication to the International Journal of Radiation Oncology • Biology • Physics (IJROBP) and describe the fate of rejected manuscripts.
Manuscripts submitted to the IJROBP from May 1, 2010, to August 31, 2010, and May 1, 2012, to August 31, 2012, were evaluated for author demographics and acceptance status. A PubMed search was performed for each IJROBP-rejected manuscript to ascertain whether the manuscript was ultimately published elsewhere. The Impact Factor of the accepting journal and the number of citations of the published manuscript were also collected.
Of the 500 included manuscripts, 172 (34.4%) were accepted and 328 (65.6%) were rejected. There was no significant difference in acceptance rates according to gender or degree of the submitting author, but there were significant differences seen based on the submitting author's country, rank, and h-index. On multivariate analysis, earlier year submitted (P<.0001) and higher author h-index (P=.006) remained significantly associated with acceptance into the IJROBP. Two hundred thirty-five IJROBP-rejected manuscripts (71.7%) were ultimately published in a PubMed-listed journal as of July 2014. There were no significant differences in any submitting author characteristics. Journals accepting IJROBP-rejected manuscripts had a lower median [interquartile range] 2013 impact factor compared with the IJROBP (2.45 [1.53-3.71] vs 4.176). The IJROBP-rejected manuscripts ultimately published elsewhere had a lower median [interquartile range] number of citations (1 [0-4] vs 6 [2-11]; P<.001), which persisted on multivariate analysis.
The acceptance rate for manuscripts submitted to the IJROBP is approximately one-third, and approximately 70% of rejected manuscripts are ultimately published in other PubMed-listed journals, but these ultimate-destination journals usually have a lower impact factor, leading to fewer citations and overall visibility.
评估提交至《国际放射肿瘤学•生物学•物理学杂志》(IJROBP)以供发表的原创稿件接受率较高所相关的特征,并描述被拒稿件的去向。
对2010年5月1日至2010年8月31日以及2012年5月1日至2012年8月31日期间提交至IJROBP的稿件进行作者人口统计学和接受状态评估。针对每篇被IJROBP拒稿的稿件在PubMed上进行检索,以确定该稿件最终是否在其他地方发表。还收集了接受该稿件的期刊的影响因子以及已发表稿件的被引用次数。
在纳入的500篇稿件中,172篇(34.4%)被接受,328篇(65.6%)被拒。根据投稿作者的性别或学位,接受率无显著差异,但基于投稿作者的国家、职级和h指数存在显著差异。多因素分析显示,较早提交年份(P<0.0001)和较高的作者h指数(P = 0.006)仍与被IJROBP接受显著相关。截至2014年7月,235篇被IJROBP拒稿的稿件(71.7%)最终发表在PubMed收录的期刊上。投稿作者的任何特征均无显著差异。接受IJROBP拒稿的期刊2013年影响因子的中位数[四分位间距]低于IJROBP(2.45[1.53 - 3.71]对4.176)。最终在其他地方发表的被IJROBP拒稿的稿件被引用次数的中位数[四分位间距]较低(1[0 - 4]对6[2 - 11];P<0.001),多因素分析时该情况依然存在。
提交至IJROBP的稿件接受率约为三分之一,约70%的被拒稿件最终发表在其他PubMed收录的期刊上,但这些最终发表期刊的影响因子通常较低,导致被引用次数较少且整体知名度较低。